

# A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses

Thomas Meunier, Lowiese Desmarets, Simon Bordage, Moussa Bamba, Kévin Hervouet, Yves Rouillé, Nathan François, Marion Decossas, Valentin Sencio, François Trottein, et al.

# ▶ To cite this version:

Thomas Meunier, Lowiese Desmarets, Simon Bordage, Moussa Bamba, Kévin Hervouet, et al.. A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses. Antimicrobial Agents and Chemotherapy, 2022, 10.1128/AAC.01581-21. hal-03447751

HAL Id: hal-03447751

https://hal.science/hal-03447751

Submitted on 24 Nov 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses Thomas Meunier<sup>†1</sup>, Lowiese Desmarets<sup>†1</sup>, Simon Bordage<sup>†2</sup>, Moussa Bamba<sup>2,3</sup>, Kévin Hervouet<sup>1</sup>, Yves Rouillé<sup>1</sup>, Nathan François<sup>1</sup>, Marion Decossas<sup>4</sup>, Valentin Sencio<sup>1</sup>, François Trottein<sup>1</sup>, Fézan Honora Tra Bi<sup>3</sup>, Olivier Lambert<sup>4</sup>, Jean Dubuisson<sup>1</sup>, Sandrine Belouzard<sup>1</sup>, Sevser Sahpaz<sup>2</sup>‡, and Karin Séron<sup>1</sup>‡\* <sup>1</sup> Univ Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France. <sup>2</sup>Univ Lille, Université de Liège, Université de Picardie Jules Verne, JUNIA, UMRT 1158 BioEcoAgro, Métabolites spécialisés d'origine végétale, F-59000 Lille, France. <sup>3</sup> UFR Sciences de la Nature, Université Nangui Abrogoua, BP 801 Abidjan 02, Côte d'Ivoire. <sup>4</sup> Univ Bordeaux, CBMN UMR 5248, Bordeaux INP, F-33600 Pessac, France. \* corresponding author E-mail: karin.seron@ibl.cnrs.fr † These authors contributed equally to this work ‡ These authors also contributed equally to this work 

# Abstract

The SARS-CoV-2 outbreak has highlighted the need for broad-spectrum antivirals against coronaviruses (CoVs). Here, pheophorbide a (Pba) was identified as a highly active antiviral molecule against HCoV-229E after bioguided fractionation of plant extracts. The antiviral activity of Pba was subsequently shown for SARS-CoV-2 and MERS-CoV, and its mechanism of action was further assessed, showing that Pba is an inhibitor of coronavirus entry by directly targeting the viral particle. Interestingly, the antiviral activity of Pba depends on light exposure, and Pba was shown to inhibit virus-cell fusion by stiffening the viral membrane as demonstrated by cryo-electron microscopy. Moreover, Pba was shown to be broadly active against several other enveloped viruses, and reduced SARS-CoV-2 and MERS-CoV replication in primary human bronchial epithelial cells. Pba is the first described natural antiviral against SARS-CoV-2 with direct photosensitive virucidal activity that holds potential for COVID-19 therapy or disinfection of SARS-CoV-2 contaminated surfaces.

# Introduction

43

The COVID-19 pandemic has highlighted the lack of specific antiviral compounds available 44 against coronaviruses (CoVs). COVID-19 is caused by the severe acute respiratory syndrome 45 coronavirus 2 (SARS-CoV-2), the third identified human CoV causing severe pneumonia (1–3). 46 47 Before 2003, coronaviruses were known to cause severe diseases in animals, but human CoVs, such as HCoV-229E and OC-43, were mainly associated with common colds, and only rarely 48 with severe outcomes (4). The severe acute respiratory syndrome coronavirus (SARS-CoV) 49 50 outbreak in 2003 was the first emergence of a highly pathogenic human CoV. The second highly pathogenic coronavirus, identified in 2012 in Saudi Arabia, is the Middle-East respiratory 51 52 syndrome coronavirus (MERS-CoV), which is still endemically present up to date. SARS-CoV-2 53 is highly related to SARS-CoV (5). The tremendous efforts of the scientific community worldwide to counteract the COVID-19 pandemic have rapidly led to the development of highly 54 efficient vaccines that are now administered worldwide. Unfortunately, the emergence of SARS-55 CoV-2 variants in different regions of the world might render the vaccines less efficient and may 56 57 necessitate a booster vaccination every year which might not be achievable for billions of human 58 beings in all parts of the world. Therefore, to get rid of this pandemic and face future epidemics, it is assumed that not only vaccination is necessary but also the availability of efficient antiviral 59 treatments. Before the emergence of SARS-CoV-2, no specific antiviral was commercially 60 61 available for treatment of CoV infections. Due to the urgent need for antivirals against SARS-62 CoV-2, many researchers have focused their investigations on repurposing available drugs. Unfortunately, until now, none of them has been able to significantly reduce severe outcomes in 63 64 patients. High content screening in vitro of approved drugs identified some potential interesting antiviral molecules that have still to be tested in clinic on patients with COVID-19 (6-8). 65 Protease and polymerase inhibitors are also widely investigated in *in vitro* studies (9). Recently, 66 White et al. identified plitidepsin, an inhibitor of the host protein eEF1A as a potential antiviral 67

68 agent for SARS-CoV-2 (10). To date, only synthetic neutralizing monoclonal antibodies have 69 been approved for emergency usage in newly infected patients. Coronavirus are members of the Coronaviridae family within the order Nidovirales. CoVs are 70 71 enveloped viruses with a positive single-stranded RNA genome of around 30 kb. The genome 72 encodes 4 structural proteins, the nucleocapsid (N), the spike (S), the envelope (E), and the 73 membrane (M) proteins. The S protein is important for the interaction of the viral particle with 74 the cellular host receptor, being angiotensin-converting enzyme 2 (ACE2) for SARS-CoVs (11, 75 12), dipeptidyl peptidase 4 (DPP4) for MERS-CoV (13) and aminopeptidase N (APN) for HCoV-229E (14). Once attached, the virus releases its genome into the cytosol by fusion of the viral 76 77 envelope with a host membrane. This fusion process is mediated by the S protein, a class I fusion 78 protein, and can occur either at the plasma- or at the endosomal membrane. Viral class I fusion 79 proteins are typically synthesized as inactive precursor proteins and require proteolytical 80 activation by cellular proteases to acquire their fusion competent state. The host-cell protease 81 TMPRSS2 has been shown to be necessary for plasma membrane fusion of many coronaviruses 82 including SARS-CoV-2 (12, 15, 16), whereas cathepsins are often involved in fusion processes at 83 endosomal membranes (17). 84 It is estimated that about 80% of the global population rely on traditional medicine to treat 85 infectious diseases. Plants are a natural source of compounds with a structural diversity that is 86 much higher than those obtained by chemical synthesis. Many of these compounds have proven 87 their antiviral activity in vitro. To date, some reports describe the antiviral activity of natural 88 compounds on coronavirus including SARS-CoV-2, but many of them are in silico analyses 89 without any in vitro or in vivo evidence (18, 19). Here we show that pheophorbide a (Pba) isolated from Mallotus oppositifolius (Geiseler) 90 91 Müll.Arg. (Mo, Euphorbiaceae) leave crude extract after bioguided fractionation has antiviral

activity against various CoVs, including HCoV-229E, MERS-CoV and SARS-CoV-2, but also

92

against other enveloped viruses, such as yellow fever virus (YFV), hepatitis C virus (HCV) and Sindbis virus (SINV). Moreover, we demonstrate that Pba is an antiviral photosensitizer directly acting on the viral particle, thereby impairing the virus-cell fusion step.

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

93

94

95

# Results

Pheophorbide a (Pba) isolated from the crude methanolic extract from Mallotus

oppositifolius (Geiseler) Müll.Arg. is highly active against HCoV-229E

Fifteen plants methanolic extracts from the Ivorian pharmacopeia, which were initially screened for their anti-HCV activity (Bamba et al., submitted), were tested against HCoV-229E-Luc, a luciferase recombinant version of HCoV-229E, which allows for a rapid and easy screening of diverse molecules in vitro. Seven of the fifteen extracts significantly reduced HCoV-229E infection (Figure 1A), whereas none of the extracts showed cytotoxicity in Huh-7 cells at the tested concentrations (Bamba et al., submitted). The Mallotus oppositifolius (Mo) crude extract was the most active and therefore selected for further analyses. A bioguided fractionation was performed to find out the active compound(s) in this plant. This revealed that the methylene chloride (MC) partition was the most active on HCoV-229E (Figure 1B) and was therefore chosen for fractionation by centrifugal partition chromatography (CPC), leading to 10 fractions (F1-F10). Among these fractions, F7 was the most active and subjected to further fractionation by preparative high performance liquid chromatography (HPLC), leading to 9 subfractions (F7.1-F7.9). F7.7 was the most active of them and seemed to contain only one molecule. This dark green product was analysed by LC-UV-MS, which revealed only one peak (m+H = 593,3) with two maxima of absorption in the visible light (409 and 663 nm). This information was used for a Dictionary of Natural Product search (https://dnp.chemnetbase.com/), indicating that this molecule could be pheophorbide a (Pba). F7.7 purity and chemical structure was further confirmed by nuclear magnetic resonance (NMR)(data not shown).

To confirm that Pba was the active compound of the Mo extract, a dose-response experiment was performed with both the pure compound isolated in F7.7 and commercial Pba against HCoV-229E-Luc in Huh-7 cells. As shown in Figure 1C, IC<sub>50</sub> values were comparable for both natural and commercial Pba (0.51  $\mu$ M and 0.54  $\mu$ M, respectively), confirming that Pba was indeed the active substance of Mo.

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

118

119

120

121

122

# Pba is active against several human CoVs at non-cytotoxic concentrations

Prior to the assessment of its broad-spectrum activity against various CoVs, the cytotoxicity of Pba was determined in different cells lines. As Pba is known to be a photosensitizer it was assumed that light could affect its toxicity. MTS assays were performed in similar conditions than the infection procedures. Cells were incubated with Pba at different concentrations and taken out of the incubator after 1 h to change the medium and left for 10 min under light exposure in the biosafety cabinet (BSC), after which they were replaced in the incubator for 23 h. In parallel, plates were kept for 24 h in the dark. Pba did not exhibit any toxicity at concentrations up to 120 µM when left in the incubator for 24 h without light exposure, whereas it showed some toxicity when the cells were shortly exposed to light, with CC<sub>50</sub> values of  $4.4 \pm 1.2 \,\mu\text{M}$ ,  $5.8 \pm 1.9$  $\mu$ M and 5.5  $\pm$  2.0  $\mu$ M for Huh-7, Vero-E6 cells, and Vero-81, respectively (Figure 2 and Figure S1). Taken together, these results show that the cytotoxicity of Pba in cell culture depends on light exposure. The antiviral activity of Pba was tested on different human CoVs. It was first confirmed on HCoV-229E by measuring infectious titers (Figure 2) with an IC<sub>50</sub> value of 0.1 µM, resulting in a selectivity index of 44. Similarly, infection inhibition assays were performed with various noncytotoxic concentrations of Pba against SARS-CoV-2 and MERS-CoV. As shown in Figure 2, Pba had a strong antiviral effect against both highly pathogenic coronaviruses at non-toxic concentrations, with IC $_{50}$  values of 0.18  $\mu$ M for both SARS-CoV-2 and MERS-CoV, resulting in a selectivity index of 32 and 24, respectively.

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

142

143

# Pba is an inhibitor of coronavirus entry by direct action on the particle

Coronaviruses fusion is triggered by proteolytic cleavage of the spike protein. Depending on cellular proteases available, fusion can occur after endocytosis of the virus or directly at the cell surface. It has been demonstrated that HCoV-229E and SARS-CoV-2 fusion at the plasma membrane depends on the expression of the TMPRSS2 protease (12, 20), and for many coronaviruses the entry via fusion at the plasma membrane has been shown to be the most relevant pathway in vivo (21). To determine if Pba was able to inhibit both entry pathways, its antiviral activity was tested in Huh-7, and Huh-7-TMPRSS2 cells, the latter being obtained after transduction with a TMPRSS2 lentiviral expression vector. Two inhibitors of the entry pathway were used as a control, E64D as inhibitor of the endocytic pathway and Camostat as inhibitor of the TMPRSS2 protease. As shown in Figure S2, E64D specifically inhibited HCoV-229E infection in Huh-7 cells whereas Camostat inhibited infection in Huh-7-TMPRSS2 cells. Complete inhibition of infection was observed when a combination of the two inhibitors was used, showing that both entry pathways can be used in vitro. No difference in antiviral activity of Pba against HCoV-229E infection was observed in the presence or absence of TMPRSS2 (Figure 3A). Similar results were obtained with SARS-CoV-2 in Vero cells (our unpublished observation). These results show that Pba exhibits antiviral activity whatever the entry pathway used. To gain insights into the mechanism of action of Pba, a time-of-addition assay with Pba was performed during HCoV-229E or SARS-CoV-2 infection. Therefore, Pba was added at different time points before, during or after inoculation. All experiments were performed under BSC's light exposure. For both viruses, no inhibition of infection was observed when Pba was added to the cells before inoculation (pre-treatment of the cells), whereas a strong inhibition of infection was noticed when Pba was present during the virus inoculation step (Figure 3B and 3C). When Pba was added only after inoculation, its inhibitory effect rapidly dropped and normal levels of infectivity were observed again when Pba was added more than 2 h after inoculation. Chloroquine is a well-known inhibitor of SARS-CoV-2 replication in vitro, as it inhibits viruscell fusion after endocytosis by preventing endosomal acidification. As shown in Figure 3C, the Pba and chloroquine inhibition curves were rather similar, showing that Pba could inhibit virus entry. It is worth noting that normal levels of infectivity were observed when Pba was added more than 2 h after inoculation, whereas chloroquine-treated cells remained at around 60% of normal levels which may be due to inhibition of the second round of entry since our experimental conditions are compatible with reinfection. Taken together, these results suggest that Pba is inhibiting virus entry. Since no antiviral activity was observed with cells treated with Pba prior to inoculation, we wondered whether Pba targets the virus instead of the cells. To test this hypothesis, HCoV-229E-Luc was pre-incubated for 30 min at a concentration 10 times higher than that used during inoculation. For this experiment, HCoV-229E-Luc was pre-incubated with Pba at 2 µM for 30 min, then diluted to reach a concentration of Pba of 0.2 µM for inoculation, a concentration which does not severely impact HCoV-229E-Luc infection as shown above. In parallel, cells were directly inoculated with HCoV-229E-Luc at 0.2 and 2 µM as a control. The results clearly show that when HCoV-229E-Luc was pre-treated with Pba at high concentration (2 µM) before inoculation at low concentration (0.2 µM), the antiviral activity was much stronger than when inoculation was performed in the presence of 0.2 µM Pba without any pre-treatment (Figure 3D). Taken together, these results indicate that Pba inhibits HCoV entry by a direct effect on the viral particle.

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

# Pba is an inhibitor of viral fusion

192

193 Virus entry can be divided into two different steps, firstly the viral attachment to the cell surface, 194 and secondly the fusion of the virus envelope with cellular membranes. To further define the 195 mode of action of Pba, experiments were performed with HCoV-229E, which can be manipulated 196 in a lower containment facility. To determine a potential effect at the attachment step, Huh-7-197 TMPRSS2 cells were incubated with HCoV-229E in the presence or absence of Pba at 4°C for 1 198 h. These conditions block endocytosis but allow virus attachment to the cell surface. Cells were 199 rinsed with PBS and the amount of virions attached to the surface was determined by 200 quantification of viral genomes by qRT-PCR. As shown in Figure 4A, only a slight and non-201 significant decrease in RNA levels was observed in the presence of Pba, indicating that Pba 202 barely affect virus attachment. The action of Pba on the fusion step was investigated in virus-cell 203 fusion assay by using trypsin as an exogenous protease to induce coronavirus membrane fusion at 204 the plasma membrane (22, 23). Huh-7 cells were treated with NH<sub>4</sub>Cl to inhibit fusion in the 205 endocytic pathway and viruses were bound at the cell surface at 4°C. Then, fusion was induced 206 by a short trypsin treatment at 37°C. Entry at the cell surface was more efficient in presence of 207 trypsin compared to the control (Figure 4B), which is consistent with other reports (22, 23). In 208 addition, Pba at both 0.5 and 1 µM strongly inhibited infection levels in trypsin-mediated fusion 209 conditions in a similar range compared to the inhibition seen with the control. Taken together, 210 these results indicate that Pba inhibits entry at the fusion step and not by preventing attachment. 211 Two viral structures are involved in the virus-cell fusion, namely the spike protein and the viral 212 membrane itself. To find out if Pba targets the spike, a cell-cell fusion assay was performed. For 213 this, the SARS-CoV-2 spike protein was transiently expressed by plasmid transfection in Vero-81 214 cells. At 6 h post-transfection, the medium was replaced with medium containing either DMSO 215 or 1 µM Pba until 24 h p.t.. As shown in Figure 4C, spike induced cell-cell fusion (apparent as 216 syncytium formation) occurred equally well in control (DMSO)- and Pba-treated conditions, indicating that Pba cannot prevent cell-cell fusion induced by the viral spike protein. Taken together these results are not in favour of an effect of Pba on the viral spike fusion protein.

219

220

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

217

218

# The antiviral activity of Pba is increased upon light exposure and targets the viral

# 221 membrane

Given that Pba is photoactivable, we wondered whether its antiviral effect is light-dependent. We therefore inoculated Huh-7 cells with HCoV-229E in the presence of Pba under different light exposure conditions. As shown in Figure S3, the antiviral activity of Pba increased upon light exposure. However, even in the dark, antiviral activity was observed at 10 µM. A typical feature of photosensitizers is that the concentration required for its biological properties decreases upon increase of time of exposure to the light. To see whether Pba behaves as other photosensitizers, HCoV-229E was pre-incubated with Pba at various concentrations (0.02, 0.2 and 2 µM) and exposed to the normal white light of the laminar flow cabinet for different durations (ranging from 5 to 80 min). It is important to note that light alone was not responsible of the antiviral activity because there was no antiviral effect after a long exposure time (80 min) with Pba at inactive concentration (0.02 µM). As shown in Figure 5A, results clearly showed that with a same concentration of Pba, increased inhibitory effect could be observed with longer light exposure times. Similar results were observed with SARS-CoV-2 (Figure 5B). Together, these data indicate that the anti-coronavirus properties of Pba depend on its dynamic photoactivation. Photodynamic inactivation (PDI) of microorganisms typically results from the onset of reactive oxygen species (ROS), including free radicals or singlet oxygen species (<sup>1</sup>O<sub>2</sub>), generated when the light-activated photosensitizer falls back to its ground state, thereby transferring its energy to molecular oxygen (resulting in the onset of <sup>1</sup>O<sub>2</sub>) or initiating photochemical reactions with ROS generation. Two mechanisms of activation have been described, either type I reactions in which the photosensitizer activates a substrate that generates reactive oxygen species (ROS), or type II reactions in which the photosensitizer directly generates singlet oxygen (<sup>1</sup>O<sub>2</sub>). Subsequently, these species can damage various micro-organism structures, such as nucleic acids, proteins or lipids (24, 25). To determine if the antiviral activity of Pba also depends on ROS or <sup>1</sup>O<sub>2</sub> generation, infection was performed in the presence of quenchers that are able to trap these generated oxygen species. Two <sup>1</sup>O<sub>2</sub> quenchers were used, a water-soluble analogue of vitamin E, Trolox, and NaN<sub>3</sub> (Figure 5C). HCoV-229E was mixed with the quenchers Trolox and NaN<sub>3</sub> both at 10 mM, and Pba was added at the inoculation step. Then the cells were rinsed and fresh culture medium was added for 6 h. The results clearly showed that both Trolox and NaN<sub>3</sub> were able to reduce the action of Pba (Figure 5C), indicating that the antiviral activity of Pba is mediated by the generation of <sup>1</sup>O<sub>2</sub> after photoactivation. Vigant et al. clearly demonstrated that the generation of <sup>1</sup>O<sub>2</sub> by the lipophilic photosensitiser LJ001 induces the phosphorylation of unsaturated phospholipid of viral membranes, and changes the biophysical properties of viral membranes, thereby affecting membrane fluidity and/or increasing rigidity (24). As a result, the change of fluidity and/or rigidity of the viral membrane impairs its ability to undergo virus-cell fusion. We therefore wondered whether a similar action of the photosensitizer on the lipids of the viral envelope might also explain our observation that Pba is able to inhibit HCoV-229E fusion by targeting the viral particle. We hypothesized that the Pba-induced membrane rigidity may render the virus less sensitive to a shrinkage effect induced by an osmotic stress. Therefore, HCoV-229E was incubated with Pba either in the dark or under light exposure for 30 min, and subjected to osmotic shock with 400 mM NaCl before fixation with 4% PFA. Fixed viral particles were visualized by cryo-electron microscopy (CryoEM). As shown in Figure 6, intact virions with their characteristic spikes at the surface can be observed in untreated conditions (control). The addition of Pba either in the dark or under light condition did not affect the overall morphology of virions in normal medium conditions. Interestingly, when intact virions were subjected to an osmotic stress by increasing NaCl concentration from 100 mM

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

to a final concentration of 400 mM, the virions shape was altered due to a shrinkage of the viral membrane. When virions incubated with Pba in the dark were subjected to osmotic shock, similar alteration of viral shape was observed. However, in the presence of Pba and under light condition, no membrane deformation was observed suggesting that the virus was more resistant to osmotic shock. These results clearly show that light-activated Pba modify the mechanical properties of the viral envelope by increasing its stiffness. This Pba-induced increase in the envelope rigidity likely prevents the membrane deformation needed to undergo virus-cell fusion. Knowing that there might be an effect of the light, the spike-induced cell-cell fusion assay as shown in Figure 4C was repeated with short light exposure of the spike-transfected cells every 2 h after addition of Pba. Even with regular exposure to the light, no effect of Pba was seen on the spike-mediated cell-cell fusion (data not shown), further excluding that Pba additionally targets the spike protein.

Pba is a broad-spectrum antiviral that targets viral membranes of several enveloped viruses. In contrast to viral proteins, viral membranes are derived from the host cell and hence are not virus specific. This suggests that Pba might have broader antiviral activity against enveloped viruses. Indeed, antiviral activities against other viruses have already been reported for Pba or related molecules. These include HCV, HIV (Human immunodeficiency virus), and IAV (Influenza A virus) (26–28). To confirm the broad-spectrum activity of Pba, its antiviral activity was tested on pseudotyped viral particles with envelope proteins of VSV (vesicular stomatitis virus), HCV, SARS-CoV-2, and MERS-CoV. Pseudoparticles were pre-treated with 0.5, 1 or 2 μM Pba and exposed or not to the light for 30 min prior to inoculation. The results clearly showed that Pba inhibited pseudoparticle infection regardless of the nature of the viral envelope protein, but only under light conditions (Figure 7A). Next, the antiviral activity of Pba was tested

for coxsackievirus (CVB4, non-enveloped), Sindbis virus (SINV, enveloped), hepatitis C virus (HCV, enveloped), and yellow fever virus (YFV, enveloped). Whereas Pba was not active on the non-enveloped virus CVB4, it showed a clear antiviral effect against the 3 enveloped viruses HCV, YFV and SINV (Figure 7B). Taken together, these results confirm the light-dependent activity of Pba on enveloped viruses and suggest that the lipid membrane is the most likely target of the compound.

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

292

293

294

295

296

297

# Other chlorophyll-derived products and photosensitizers possess a light-dependent anticoronaviral activity

Pba is a break-down product of chlorophyll. Chlorophyll is metabolized into different compounds including Pba, pyropheophorbide a (pyroPba), and chlorin e6. We wondered if these products activity. Furthermore, we selected nine porphyrins or would also have antiviral metalloporphyrins structurally related to Pba (N-methyl protoporphyrin IX, N-methyl mesoporphyrin IX, Zn-protoporphyrin IX, tin-mesoporphyrin IX, temoporfin, phthalocyanine, hemin chloride, HPPH, and 5,15-DPP), and one photosensitizer without related structure (Rose Bengale) to determine if similar antiviral activity against coronaviruses could be identified. The toxicity and antiviral activity of these compounds were investigated (Figure S4). Chlorophyll b, phthalocyanine and 5,15-DPP were not active at the tested concentrations. Three molecules, hemin chloride, temoporfin and Rose Bengale had a moderate antiviral activity. The antiviral activity of the six most active compounds was tested both under normal white light conditions and in the dark, clearly showing that, similar to Pba, the antiviral activity of most molecules tested was also light-dependent (Figure S3). Interestingly, N-methyl protoporphyrin IX and Nmethyl mesoporphyrin IX showed an antiviral activity in dark conditions, but much lower than under light exposure. PyroPba was toxic at tested concentrations, thus dose-response experiments with lower concentrations were performed to determine precise CC<sub>50</sub> and IC<sub>50</sub>. This was also done for all the active compounds. The  $CC_{50}$  and  $IC_{50}$  of the different compounds were compared and only pyroPba was more active against HCoV-229E than Pba (Table 1) with an  $IC_{50}$  of 0.35  $\mu$ M. However, this compound is also more toxic with a  $CC_{50}$  of 2.67  $\mu$ M and a selective index of 7.6. Thus, our results show that porphyrin-related compounds have antiviral activity against HCoV-229E but that Pba and pyroPba are the most active under normal white light exposure.

 $\begin{tabular}{ll} Table 1. Inhibitory and cytotoxic concentrations, and selective index of photosensitizers against HCoV-229E \\ \end{tabular}$ 

Molecules	IC <sub>50</sub> (µM)	CC <sub>50</sub> (µM) 24 h	SI
Pba	0.54	6.08	11.2
PyroPba	0.35	2.67	7.6
Chlorin e6	0.72	21.4	29.7
НРРН	1.14	8.13	7.1
N-methyl protoporphyrin IX	1.21	ND > 80	>66.1
N-methyl mesoporphyrin IX	1.25	ND > 80	>64
Zn protoporphyrin IX	0.79	16.64	21.0
Rose Bengale	2.86	ND > 80	27.9

# Pba reduces SARS-CoV-2 and MERS-CoV replication in human primary airway epithelial cells

As shown above, Pba is able to inhibit SARS-CoV-2 and MERS-CoV infection under white light exposure in cell culture. To determine if Pba could be used *in vivo*, its antiviral activity was tested in a preclinical model, the human primary airway epithelial cells. These cells, Mucilair<sup>TM</sup>, are primary bronchial epithelial cells reconstituted in a 3D structure to mimic bronchial epithelium with an air-liquid interface. Mucilair<sup>TM</sup> cells were inoculated with SARS-CoV-2 or MERS-CoV in the presence of Pba at 0.25 or 2.5 μM. Remdesivir at 5 μM was used as a positive control. At 72 h post-inoculation, viral titers were determined and viral RNA levels were quantified. Viral RNA levels of SARS-CoV-2 and MERS-CoV were significantly decreased in cells in the

presence of Pba at 0.25 and 2.5 μM, respectively (Figure 8A). Similarly, viral titers of both viruses were decreased of more than 1xLog10 in the presence of Pba at 2.5 μM (Figure 8B). In parallel, the toxicity of Pba was measured in Mucilair<sup>TM</sup> by measuring lactate deshydrogenase (LDH) secretion and trans-epithelial electrical resistance. Cells were incubated with the molecule in the same condition as the infection assay. Cells treated with lysis buffer were used as a control. No toxicity was observed up to 72h in the cells treated with Pba compared to the control (Figure 8C and 8D). In cells treated with lysis buffer, no LDH secretion was observed at 48h and 72h because the cells were dead. Taken together, these results confirm the antiviral activity of Pba against highly pathogenic human CoVs and its potential activity *in vivo*.

# **Discussion**

By screening plant extracts for their antiviral activity against coronaviruses, the present study identified Pba as the active antiviral compound in the crude methanol extract from *M. opositifolius* after bioguided fractionation. It was demonstrated that Pba is active against various human CoVs, including SARS-CoV-2, HCoV-229E and MERS-CoV, as well as other enveloped viruses, including HCV, SINV and YFV, and various pseudotyped particles. Furthermore, we characterized Pba as a broad-spectrum antiviral photosensitizer causing PDI of all tested enveloped viruses by production of singlet oxygen species that most probably increase the rigidity of the lipid bilayer of the viral envelope.

Pba is a product of chlorophyll breakdown which is abundantly present in various plants (such as spinach) and marine algae. In general, the chlorophyll content in plants may vary and depends on the season, the part of the plant, the maturity of the organs and many other factors (29, 30). Chlorophyll is degraded into Pba by chlorophyllase and some plants with high chlorophyllase content may contain more Pba (31, 32). Pba is well documented for its potential as anti-cancer

agent in photodynamic therapy (PDT). It is known to have a low toxicity, to selectively accumulate in tumours and to have a high adsorption at 665 nm (33, 34).

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

For many years, photosensitizers have mainly been used as antitumor therapy, for which many photosensitizers have already been proven to be clinically safe and some are currently approved for use in humans (35). Although reports on the PDI of viruses go back to 1960, where it was shown that some photosensitive dyes, such as methylene blue, had an antiviral effect, it is only in the last decades that photosensitizers have gained considerable interest as antimicrobial (bacteria, fungi, and viruses) agents, due to their strong antimicrobial effects and low toxicity in normal tissue (36, 37). A major advantage of those molecules is that, due to their direct damaging effect on the micro-organism, they are insensitive to the onset of resistance of the microorganism against the compound, the latter being a major problem in today's research on antivirals and antibiotics. With the present study, we add Pba to the list of photosensitizers with considerable antiviral effects, at least against enveloped viruses. This antiviral effect is not new, since the antiviral activity of Pba has already been demonstrated before against several enveloped viruses, including HCV, Influenza A, herpes simplex-2 virus, and HIV-1 (26–28). Zhang et al (28) also showed a direct action on the viral particle, which is in line with our results. In our study, we show that the coronavirus' envelope remains intact after treatment with Pba up to 10 µM for 30 min in the light, that Pba treatment does not affect attachment, but that the virus-cell fusion is impaired probably due to the rigidification of the virus membrane upon light exposure. In addition, there seemed to be a slight antiviral effect at high concentrations (more than 10 µM) even in dark conditions. In contrast to our results, some papers show that Pba has a virucidal activity by damaging the virus envelope, thereby inhibiting attachment (28). For HCV and HIV-1, Pba and chlorophyll a derivates were applied after virus infection and were shown to act on replication corresponding to a mode of action different than the one reported in our study. Furthermore, none of those reports showed a mechanism of action dependent on light exposure, and hence did not show that the antiviral effect is mediated by PDI of the particle. It is important to note that under usual experimental conditions, cell cultures were not protected from light, thus is likely that the vast majority of the reports on antiviral activity of Pba were performed under light exposure. Due to the lack of control conditions in the dark or information on the time of (unnoticed) light exposure in the above mentioned reports on Pba, it is very hard to compare our data with the literature at this moment. More in depth studies will be needed to understand and compare the action of Pba on different viruses, in both light and dark conditions.

It is interesting to note that Pba (or highly related compounds such as pyroPba) has been isolated from different plant species and different organisms including marine algae (38), rendering Pba a very attractive antiviral due to its high availability. Moreover, it has been postulated that Pba can transport a metal ion like zinc inside the cell and that zinc can inhibit viral replication (39) which might be another advantage to use these molecules as antivirals. In our study, it was confirmed that neither natural nor commercial Pba used in our experiments contained a metal ion, so future studies should be performed with zinc Pba to demonstrate this hypothesis.

Here, we show that Pba inhibits virus-cell fusion, probably by targeting and photodynamically damaging the viral membrane. With the help of cryo-EM, we demonstrated that the treatment of virions with Pba and exposed to the light did not affect their shape despite an osmotic shock. This is an indirect demonstration of an increased rigidity of the viral envelope upon Pba treatment. This feature was already demonstrated using a biophysical approach with lipophilic photosensitizers with antiviral activity (24, 40). It was postulated that the increased rigidity impairs membrane bending required for viral fusion (41). Contrary to the cell membrane, the viral envelope is not able to undergo regeneration, which renders the PDI virus specific and insensitive to the onset of resistance. Very recently, Tummino *et al.* suggested that many repurposed drugs targeted as SARS-CoV-2 antivirals are cationic amphiphilic drugs (CAD),

which induce phospholipolysis (42). CAD are host target antivirals that have an action on cell phospholipids, provoke phospholipidosis and disrupt double membrane vesicles necessary for viral replication. The mechanism of action of the CAD is different from the one of Pba. Pba is a virus target antiviral, and it was never reported to have a phospholipidosis activity. Pba most probably induces an oxidation of the viral envelope phospholipids and, as it was shown by cryoEM in our study, does not induce phospholipidosis.

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

411

412

413

414

415

416

In the present study, several other compounds structurally related to Pba and to other known photosensitizers were also screened for their anti-coronavirus activity in order to find out whether other compounds would have a more potent effect. Several of those compounds, including pyroPba, chlorin e6, or HPPH, N-methyl protoporphyrin IX, N-methyl mesoporphyrin IX, and Zn-protoporphyrin IX had a light-dependent antiviral effect, but only pyroPba turned out to be more active than Pba. However, pyroPba was also more toxic, and hence the final selectivity index was not higher than that of Pba. Several chlorophyll derivates like pyroPba and pheophytin a have already been demonstrated to be active against IAV, herpes simplex-2 virus, HCV, RSV (respiratory syncytial virus), and SARS-CoV-2 (26, 27, 43). The authors studied the mechanism of action of pyroPba against IAV and showed that the molecule targets the membrane of the virus and not the surface glycoproteins, a mechanism which is consistent with the one that we observed for Pba in our study. A requirement for photo-activation of pyroPba was not investigated nor mentioned by Chen et al. (43). Chlorophyllides, chlorophyll precursors, are another class of chlorophyll derivates that have been shown to have antiviral activity against several viruses including hepatitis B virus (44-46). Other porphyrins have already been described for their antiviral activity (25, 47). Interestingly, three photosensitizers which have been shown to be active against VSV, including N-methyl protoporphyrin IX, N-methyl mesoporphyrin IX, and Zn-protoporphyrin IX, were also identified in our screen (48). The authors clearly demonstrated that these compounds inactivated VSV after photoactivation via singlet oxygen release. We did not demonstrate the mechanism of action of these three molecules against HCoV-229E but we also demonstrated that they are active after photoactivation. Very recently, protoporphyrin IX and verteporfin were identified as inhibitors of SARS-CoV-2 (49, 50). Both studies showed that protoporphyrin IX is active at an early step of infection, probably the entry step. Gu et al. postulated that the interaction of the compounds with ACE2 might impair the interaction of the virus with its receptor (49). Lu et al. showed that protoporphyrin IX is active against several enveloped viruses but that the activity of protoporphyrin IX against IAV is not dependent on light activation (50). Chlorin e6 is one of the most active compounds against HCoV-229E identified in this study. The antiviral activity of chlorin e6 against enveloped viruses such as HBV (Hepatitis B virus), HCV, HIV, DENV (dengue virus), MARV (Marburg virus), TCRV (tacaribe virus) and JUNV (Junin virus) has been already demonstrated (46). Interestingly the authors also showed that the molecule is inactive against non-enveloped viruses, suggesting that it targets the viral envelope. As mentioned above, many other photosensitizers have been studied for their antiviral activity (25, 41), and for some of them, the PDI was clearly demonstrated as the mechanism of action (41, 51). In light of the current SARS-CoV-2 pandemic, photosensitizers have received renewed attention as antiviral strategies to face this pandemic, and the use of those substances for the treatment of COVID-19 or the inactivation of SARS-CoV-2 on surfaces or in water has been postulated (52, 53). Pba might have some advantages above the already described photosensitizers, as it is a highly available natural product and active under normal light conditions. Importantly, it does not require a very specific wavelength-dependent illumination treatment, at least not when applied on surfaces/mucosae exposed to the environmental light, with an absorption at 667 nm. However, the light-dependency of such molecules might render their application as therapeutic agents for internal organs (such as lungs for SARS-CoV-2) more

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

challenging. Indeed, additional illumination will make its application as real therapy more complex, though not impossible because PDT is already used for the treatment of lung cancer (54). Efforts should be made for the development of specific device allowing PDT for COVID patients. Nonetheless, we believe that broad-spectrum, low-toxic, non-resistance inducing molecules such as Pba can certainly prove their value to reduce environment-to-person and person-to-person transmission of microorganisms when applied as e.g a spray for decontamination of surfaces or when formulated for topical application in nose and mouth. Very recently, a study describing such topical application of synthetic SARS-CoV-2 fusion inhibitor has demonstrated that the topical treatment of upper respiratory tract infections might prove its value in reducing virus transmission, particularly in cases where many people gather (55). In contrast to the SARS-CoV-2 fusion inhibitor described by de Vries et al. (55), Pba is a widely commercially available natural molecule with broad-spectrum activity against many enveloped viruses. Therefore, one should explore whether it can exert similar effects upon topical administration to the nose or oral cavity. If so, Pba might help to make people less susceptible to and/or less contagious upon upper respiratory infections with enveloped viruses, many of them causing seasonal outbreaks of respiratory disease such as common colds and flu. Given that 1) onset of resistance to this product is very unlikely, 2) the activity of the compound is not dependent of envelope variants, 3) coronaviruses and other enveloped viruses can cause major problems in animals and 4) there is a potential risk for virus transmission from those animal to humans, the possibility to formulate Pba in such a way that also veterinary medicine and facilities with large numbers of animals can benefit from the strong antiviral properties that this molecule might have in the environment (decontamination of air, water and surfaces) should

484

485

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

# **Materials and Methods**

additionally be explored.

# Chemicals

Dulbecco's modified Eagle's medium (DMEM), Opti-MEM, phosphate buffered saline (PBS), 4',6-diamidino-2-phenylindole (DAPI), were purchased from Life Technologies. Goat and foetal bovine sera (FBS) were obtained from Eurobio. Pheophorbide a (Pba) >90% pure, pyroPba, chlorin e6, HPPH, N-methyl protoporphyrin IX, N-methyl mesoporphyrin IX, and Zn protoporphyrin IX were from Cayman chemicals (Merck Chemicals, Darmstadt, Germany). Remdesivir (GS-5734) was from Selleck Chemicals (Houston TX). Mowiol 4-88 was obtained from Calbiochem. Rose Bengale, trolox and other chemicals were from Sigma (St. Louis, MO). Stocks of compounds were resuspended in dimethylsulfoxide (DMSO) at 50 mM. Plant extracts were resuspended in DMSO at 25 mg/mL.

# **Antibodies**

Mouse anti-HCV E1 mAb A4 (56) and mouse anti-YFV E mAb 2D12 (anti-E, ATCC CRL-1689) were produced *in vitro* by using a MiniPerm apparatus (Heraeus). Mouse anti-dsRNA mAb (clone J2) was obtained from Scicons. Mouse anti-SARS-CoV-2 spike protein mAb were obtained from GeneTex. Polyclonal rabbit anti-SARS-CoV-2 nucleocapsid antibodies were from Novus. Cyanine 3-conjugated goat anti-mouse IgG and HRP-labeled goat-anti rabbit IgG antibodies were from Jackson Immunoresearch.

# **Cells and culture conditions**

Huh-7, Vero-81 (ATCC number CCL-81) and Vero-E6 were grown in DMEM with glutaMAX-I and 10% FBS in an incubator at 37°C with 5% CO<sub>2</sub>. Vero-81 cells were subcloned to obtain a better overall infection rate. The primary human bronchial epithelial cells Mucilair<sup>TM</sup> were from Epithelix (Geneva, Switzerland) and maintained in Mucilair<sup>TM</sup> culture medium (Epithelix) as recommended by the manufacturer.

#### Plant collection and extraction

The fifteen plants were collected in the Bafing region (North-West Côte d'Ivoire, Touba department). They were authenticated at the Centre National de Floristique (CNF), University of Félix Houphouët Boigny de Cocody (Abidjan), where voucher specimens were deposited in an Herbarium. *M. oppositifolius* voucher number is UCJ006172. Plants were cleaned and air-dried at constant temperature (26°C) for 1 to 2 weeks at the Nangui Abrogoua University (Abidjan). They were then powdered and stored in the dark until extractions. For each plant, 20 g of dried powder were mixed with 100 mL methanol for 24 h. After filtration, the grounds were extracted again twice in the same way. The 3 resulting filtrates were combined and dried under vacuum at 40°C. These extracts were then dissolved in DMSO for antiviral assays.

# Bioguided fractionation of Mo extract and Pba identification

For *Mallotus oppositifolius*, three other solvents were used to extract more compounds from these plant leave: methylene chloride (MC) for the first extraction of the dried leaves, then methanol to extract the first ground, and ethanol/water (50:50) to extract the second ground. The corresponding extracts were tested against HCoV-229E-Luc. Since the MC extract was the most active, it was fractionated by chromatography (CPC), leading to 10 fractions (F1-10) that were tested again. F7 was selected for further fractionation by another chromatography (HPLC) and led to 9 partitions (7.1-7.9). Partition 7.7 (the most active against HCoV-229E) purity and identity was determined by UPLC-MS and NMR (more details in supplementary materials).

### Viruses

The following viral strains were used: HCoV-229E strain VR-740 (ATCC), and a recombinant HCoV-229E-Luc (kind gift of Pr. V. Thiel) (57); SARS-CoV-2 (isolate SARS-CoV-

2/human/FRA/Lille\_Vero-81-TMPRSS2/2020, NCBI MW575140) was propagated on Vero-81-TMPRSS2 cells. MERS-CoV was recovered by transfecting the infectious clone of MERS-CoV-EMC12 (kindly provided by Dr Luis Enjuanes) in Huh-7 cells. A cell culture-adapted strain (JFH1-CSN6A4) of HCV was produced as previously described (58). A recombinant Sindbis virus (SINV) expressing HCV E1 glycoprotein was employed as previously described (59). Yellow fever virus strain 17D (YFV) was obtained from Dr Philippe Desprès (Institut Pasteur de Paris, France). Coxsackievirus B4 strain E2 (CVB4) was provided by Dr Didier Hober (Université de Lille, France).

# Cell toxicity assay

6×10<sup>4</sup> Huh-7, Vero-E6 and Vero-81 cells were seeded in 96-well plates and incubated for 16 h at 37°C 5% CO<sub>2</sub> incubator. The cells were then treated with increasing concentrations of the compound of interest. One hour after inoculation, cells were taken out of the incubator to be exposed to the white light of the biosafety cabinet (BSC) for 10 min, after which cells were further incubated in the dark at 37°C 5% CO<sub>2</sub> for 23 h. The BSC's light source lamp consists of one fluorescent tube of 36W, 3350 lumen white light. An MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]-based viability assay (Cell Titer 96 Aqueous non-radioactive cell proliferation assay, Promega) was performed as recommended by the manufacturer. The absorbance of formazan at 490 nm was detected using a plate reader (ELX 808 Bio-Tek Instruments Inc). Each measure was performed in triplicate and each experiment was repeated at least 3 times.

# Micilair<sup>TM</sup> toxicity assays

# 559 LDH secretion assay

Mucilair<sup>TM</sup>, three wells per condition, were incubated with Pba in 100 μl Mucilair<sup>TM</sup> culture medium, or 50 μl of lysis solution (Cytotoxicity LDH assay kit-WST, Dojindo) at the apical surface for 1 h. Pba or lysis solution was removed and the cells were placed in the incubator for 72 h. At 24 h, 48 h and 72 h. LDH secretion was measured in the basolateral medium according to the manufacturer's instructions, by recording the absorbance of WST-formazan at 490 nm as described. The results are expressed relative to the LDH secretion values obtained in the lysed wells, for which a value of 100% toxicity was attributed.

# Trans-epithelial electrical resistance

Mucilair<sup>TM</sup> were incubated with Pba and lysis solution as described above. Trans-epithelial electrical resistance was measured using a volt/ohm meter and electrode (Millicell ERS2, Millipore) at 24 h, 48 h and 72 h. 200 µl of prewarmed Mucilair<sup>TM</sup> culture medium was added at the apical surface prior resistance measurement. Data are expressed relative to control untreated cells.

# **HCoV-229E** infection inhibition assays

# Luciferase assay

HCoV-229E-Luc was first mixed with the crude extracts or the compounds at the appropriate concentrations for 10 minutes. Huh-7 cells and Huh-7-TMPRSS2 cells were inoculated with HCoV-229E-Luc at a MOI of 0.5 in a final volume of 50 μL for 1 h at 37°C in the presence of the plant crude extracts or the different compounds. The virus was removed and replaced with culture medium containing the extracts or the different compounds for 6 h at 37°C. Cells were lysed in 20 μL of Renilla Lysis Buffer (Promega, Madison, USA) and luciferase activity was quantified in a Tristar LB 941 luminometer (Berthold Technologies, Bad Wildbad, Germany) using Renilla Luciferase Assay System (Promega) as recommended by the manufacturer.

This experiment was either performed under white light exposure, in which the virus and the compounds were exposed to the light of the BSC lamp. To maximize light exposure, the tubes were laid flat on the bench of the BSC. For dark condition, the light of the BSC and the room was shut down and all the tubes and plates were covered with foil paper.

# HCoV-229E titers

Huh-7 and Huh-7-TMPRSS2 cells seeded in 24-well plates were inoculated with HCoV-229E at a MOI of 0.5 in the presence of Pba at different concentrations for 1 h at 37°C. The inoculum was removed and replaced with culture medium containing Pba and the cells were incubated at 37°C for 8 h (for TMPRSS2 condition) or 10 h (without TMPRSS2). Supernatants were collected and serial dilutions were performed and used to infect naive Huh-7 cells in 96-well plates. Six days after infection, cytopathic effect was determined in each well to calculate TCID<sub>50</sub> titers by using the Reed and Muench method.

# SARS-CoV-2 and MERS-CoV infection inhibition assays

Vero-E6 and Huh-7 cells seeded in 24-well plates 24 h before inoculation were inoculated with SARS-CoV-2 and MERS-CoV, respectively, at a MOI of 0.3 in the presence of Pba at different concentrations for 1 h at 37°C. Then, the inoculum was removed by 3 washings with DMEM and fresh medium containing different Pba concentrations was added for 16 h at 37°C. Cell supernatants were collected and the amount of infectious virus was determined by infectivity titration. Therefore, Vero-E6 (SARS-CoV-2) and Huh-7 (MERS-CoV), seeded in 96-well plates, were inoculated with 100  $\mu$ L of 1/10 serially diluted supernatants (ranging from 10<sup>-1</sup> to 10<sup>-8</sup>). Cells were incubated with the virus dilutions for 5 days at 37°C and 5% CO<sub>2</sub>. Then, the 50% tissue culture infectious dose (TCID<sub>50</sub>) was determined by assessing the CPE in each well by light microscopy and the 50% end point was calculated according to the method of Reed and Muench.

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

# Time-of-addition assay

To determine at which stage of the replication cycle Pba executed its effect, a time-of-addition assay was performed for which 1µM Pba (and 10 µM chloroquine as a control for SARS-CoV-2) was added at different time points before (referred to as the condition 'pre-treatment cells'), during (referred to as the condition 'inoculation'), or after inoculation. For the latter condition, Pba and chloroquine were not added before and during inoculation, but only directly after removal of the inoculum (referred to as the condition 'p.i. - end'), or from 1 h or 2 h after removal of the inoculum onwards (referred to as the condition '1 h p.i.-end' and '2 h p.i.-end, respectively) and were left in the medium for the rest of the incubation time (i.e until 6 h p.i. for HCoV-229E and 16 h p.i. for SARS-CoV-2). For this experiment, Huh-7-TMPRSS2 or Vero-81 cells were inoculated with HCoV-229E-Luc or SARS-CoV-2 at a MOI of 0.5 and 0.05, respectively. One hour after inoculation, cells for all conditions were washed 3 times to remove the unbound particles. HCoV-229E-luc, luciferase activity was quantified as described ahead. For SARS-CoV-2, cells were washed once with PBS and lysed in 200 µL of non-reducing 2x Laemmli loading buffer. Lysates were incubated at 95°C for 30 min to inactivate the virus and lysates were kept at -20°C until western blot analysis (see below). For each time point, DMSO was taken as a control, and all experiments were repeated 3 times.

628

629

630

631

632

633

634

627

# Western blot detection of the SARS-CoV-2 nucleocapsid expression

Sixteen hours after inoculation, cells were washed once with PBS and lysed in 200 µL of non-reducing 2x Laemmli loading buffer. Lysates were incubated at 95°C for 30 min to inactivate the virus and the proteins were subsequently separated on a 12% polyacrylamide gel by SDS-PAGE. Next, proteins were transferred to a nitrocellulose membrane (Amersham), and the membranes were subsequently blocked for 1 h at RT in 5% (w/v) non-fat dry milk in PBS with 0.1% (v/v)

Tween-20. Membranes were incubated overnight at 4°C with polyclonal rabbit anti-SARS-CoV-2 nucleocapsid antibodies in 5% (w/v) non-fat dry milk in PBS with 0.1% (v/v) Tween-20. After being washed 3 times with PBS with 0.1% (v/v) Tween-20, membranes were incubated for 1 h at RT with HRP-labeled goat-anti rabbit IgG antibodies, after which membranes were washed 3 times. N proteins were visualized by enhanced chemiluminescence (Pierce™ ECL, ThermoFisher Scientific). Quantification was performed by using Image J and its gel quantification function.

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

635

636

637

638

639

640

# Infection assay with other viruses

Vero (YFV, SINV, CBV4) or Huh-7 (HCV) cells grown on glass coverslips were infected with viral stocks diluted so as to obtain 20-40% infected cells in control conditions. The cells were fixed at a time that allowed for a clear detection of infected cells vs non-infected cells, and avoided the detection of reinfection events, thus limiting the analysis to a single round of infection (30 h p.i. for HCV, 20 h p.i. for YFV, 6 h p.i. for SINV, 4 h p.i. for CVB4). The cells were fixed for 20 min with 3% PFA. They were then rinsed with PBS and processed for immunofluorescence as previously described (60) using primary mouse antibodies specific to HCV E1 (for both HCV and SINV), YFV E, or dsRNA (for CVB4), followed by a cyanine-3conjugated goat anti-mouse IgG secondary antibody for the detection of infected cells. Nuclei were stained with DAPI. Coverslips were mounted on microscope slides in Mowiol 4-88containing medium. Images were acquired on an Evos M5000 imaging system (Thermo Fisher Scientic) equipped with light cubes for DAPI, and RFP, and a 10× objective. For each coverslip, a series of six 8-bit images of randomly picked areas were recorded. Cells labelled with anti-virus mAbs were counted as infected cells. The total number of cells was obtained from DAPI-labelled nuclei. Infected cells and nuclei were automatically counted using macros written in ImageJ. Infections were scored as the ratio of infected over total cells. The data are presented as the percentage of infection relative to the control condition.

# Effect of Pba on pseudotyped virion entry

Particles pseudotyped with either SARS-CoV-2 S (SARS-2pp), MERS-CoV S proteins (MERSpp), HCoV-229E-S (HCoV-229Epp), genotype 2a HCV envelope proteins (HCVpp), or the G envelope glycoprotein of vesicular stomatitis virus (VSV-Gpp) were produced as previously described (22, 61). Pseudotyped virions were pre-treated with Pba for 30 min at room temperature under the BSC's light or covered in foil and then used to inoculate Huh-7 cells in 96-well plates for 3 h. The inoculum was removed and cells were further incubated with culture medium for 45 h. Cells were lysed and luciferase activity was detected by using a Luciferase Assay kit (Promega) and light emission measured by using a Tristar LB 941 luminometer (Berthold Technologies).

# White light exposure kinetics

HCoV-229E-Luc or SARS-CoV-2 were pre-treated with Pba at room temperature and exposed to BSC's white fluorescent light during different period of time. To maximize light exposure, tubes were laid flat under the BSC's light. Next, infection was quantified for each virus as described previously.

# **Fusion assay**

Cells were preincubated for 30 min in the presence of 25 mM NH<sub>4</sub>Cl at 37°C to inhibit virus entry through the endosomal route, and then were transferred to ice. In the meantime, the virus was preincubated under light with Pba and 25 mM NH<sub>4</sub>Cl for 10 min and then allowed to bind to the cells at 4°C for 1 h in DMEM containing 0.2% BSA, 20 mM Hepes, and 25 mM NH<sub>4</sub>Cl. Cells were then warmed by addition of DMEM containing 3 µg/mL trypsin, 0.2% BSA, 20 mM Hepes, and 25 mM NH<sub>4</sub>Cl and were incubated for 5 min in a water bath at 37°C. The cells were

rinsed and further incubated for 30 min in culture medium containing 25 mM NH<sub>4</sub>Cl, and then the medium was replaced by normal culture medium. Seven hours after inoculation, luciferase activity was detected by using a Renilla Luciferase Assay Kit (Promega).

# Cell-cell fusion assay by transient expression of the SARS-CoV-2 spike protein

Vero-81 cells were seeded on coverslips in 24-wells 16 h before transfection. Cells were transfected with 250 ng of a pCDNA3.1(+) vector encoding for the SARS-CoV-2 spike protein using the TransIT®-LT1 Transfection Reagent (Mirus Bio). Six hours post transfection (p.t.), transfection medium was replaced by normal medium containing 1 μM Pba or DMSO. Twenty-four hours p.t., cells were fixed with 3% paraformaldehyde in PBS for 20 min at RT and syncytia were visualized by immunofluorescence, by incubating the cells with a monoclonal anti-SARS-CoV-2-spike antibody in 10% normal goat serum, followed by incubation with Cyanine-3-conjugated goat anti-mouse IgG antibodies. Nuclei were visualized with 1 μg/ml of 4',6-diamidino-2-phenylindole (DAPI), and coverslips were mounted in Mowiol® mounting medium. Pictures were obtained with an Evos M5000 imaging system (Thermo Fisher Scientific).

# Attachment assay

Huh-7-TMPRSS2 cells seeded in 24-well plates were inoculated with HCoV-229E at a MOI of 4 on ice in the presence of 4.1 or 8.2  $\mu$ M Pba under the light of the BSC. 1 h after inoculation, cells were washed 3 times with cold PBS, and lysed using LBP lysis buffer for RNA extraction following manufacturer's instructions (NucleoSpin® RNA plus extraction kit, Macherey-Nagel). Reverse transcription was then performed on 10  $\mu$ L of RNA using High Capacity cDNA Reverse Transcription kit (Applied Biosystems). 3  $\mu$ L of cDNA were used for real-time reverse-transcription polymerase chain reaction (qRT-PCR) assay using specific primers and probe

targeting the N gene (forward primer 5'-TTCCGACGTGCTCGAACTTT-3', reverse primer 5'CCAACACGGTTGTGACAGTGA-3' and probe 5'-6FAM-TCCTGAGGTCAATGCA-3') and
subjected to qPCR amplification with Tagman Master mix.

# **Quencher Assay**

HCoV-229E-Luc was mixed with 10 mM Trolox or NaN<sub>3</sub> after which 0.5 or 1 μM Pba was added and the mixture was exposed to light for 10 min. The mixture was used to inoculate Huh-7-TMPRSS2 cells for 1h. Inoculum was replaced with DMEM and cells were kept in the dark at 37°C 5% CO<sub>2</sub> for 7 h and then lysed to quantify luciferase activity as described above.

# CryoEM

HCoV-229E was produced by inoculating a confluent Huh-7 T75 Flask at MOI of 0.008 in DMEM supplemented with 5% FBS and put at 33°C 5% CO<sub>2</sub> for 5 days. Supernatant was harvested and treated with DMSO or 10 μM Pba, and further kept in the dark or exposed to light for 30 min. Then NaCl was added to a final concentration of 400 mM final to induce an osmotic shock. Viruses were fixed in 4% PFA. For cryo-EM experiments of the particles, lacey carbon formvar 300 mesh copper grids were used after a standard glow discharged procedure. Plunge freezing was realized using the EM-GP apparatus (Leica). Specimens were observed at −175 °C using a cryo holder (626, Gatan), with a ThermoFisher FEI Tecnai F20 electron microscope operating at 200 kV under low-dose conditions. Images were acquired with an Eagle 4k x 4k camera (ThermoFisher FEI).

# Primary airway cell infection quantification

The air interface of Mucilair<sup>TM</sup> (Epithelix) was rinsed with 100 μL of Mucilair<sup>TM</sup> culture medium for 10 min 3 times to remove mucosal secretion. The cells were then inoculated at the apical

734 membrane with SARS-CoV-2 or MERS-CoV at a MOI of 0.2 in the presence of compounds for 735 1 h at 37°C. Inoculum was removed and the cells were rinsed with PBS. In parallel, compounds 736 were added in the basolateral medium. 72 h post-infection, viruses secreted at the apical 737 membrane were collected by adding 200 µL of medium in the apical chamber. Viral titers were 738 determined as described above. In parallel, cells were lysed with lysis buffer from the kit NucleoSpin® RNA Plus (Macherey Nagel), and total RNA extracted following manufacturer's 739 740 instructions, eluted in a final volume of 60 µL of H<sub>2</sub>O, and quantified. 741 For SARS-CoV-2, one-step qPCR assay was performed using 5 µL of RNA and Takyon Low rox one-step RT probe Mastermix (Eurogentec) and specific primers and probe targeting E gene, 742 743 forward primer 5'-ACAGGTACGTTAATAGTTAATAGCGT-3', reverse primer 744 ATATTGCAGCAGTACGCACACA-3' and probe FAM-ACACTAGCCATC-745 CTTACTGCGCTTCG-MGB. 746 For MERS-CoV and RPLP0 reference gene, 10 µM of RNA were used for cDNA synthesis using 747 High Capacity cDNA Reverse Transcription kit (Applied Biosystems). 3 µL of cDNA were used 748 for real-time reverse-transcription polymerase chain reaction (qRT-PCR) assay using specific 749 probes. For MERS-CoV, the following primers and probe targeting N gene were used, forward 750 primer 5'-GGGTGTACCTCTTAATGCCAATTC-3', reverse primer 5′-751 TCTGTCCTGTCTCCGCCAAT-3' and probe 5'-FAM-ACCCCTGCGCAAAATGCTGGG-752 MGBNFQ-3' and subjected to qPCR amplification with Tagman Master mix. For RPLP0, 753 Tagman gene expression assay (Life Technologies) was used according to the manufacturer 754 instruction. SARS-CoV-2 E and MERS-CoV N gene expression were quantified relative to 755 RPLP0 using ΔΔCt method. A value of 1 was arbitrary assigned to infected cells without 756 compound.

758

Values were graphed and  $IC_{50}$  calculated by non-linear regression curve fitting with variable slopes constraining the top to 100% and the bottom to 0%, using GraphPad PRISM software. Kruskal Wallis nonparametric test followed by a Dunn's multicomparison post hoc test with a confidence interval of 95% was used to identify individual difference between treatments. P values < 0.05 were considered as significantly different from the control.

# **Acknowledgments**

We thank Volker Thiel for providing HCoV-229E-RLuc, Philippe Desprès for YFV, Luis Enjuanes for MERS-CoV and Didier Hober for CVB4. We are also grateful to Robin Prath and Nicolas Vandenabele for their technical help in the BSL3 facility. Authors are grateful to the LARMN platform (University of Lille, France) and wish to thank N. Azaroual and V. Ultré for their help on NMR analysis.

### 773 References

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,
   Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from
   Patients with Pneumonia in China, 2019. N Engl J Med 382:727–733.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu
   T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang
   G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with
   2019 novel coronavirus in Wuhan, China. The Lancet 395:497–506.
- Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, Du B, Li L,
   Zeng G, Yuen K-Y, Chen R, Tang C, Wang T, Chen P, Xiang J, Li S, Wang J, Liang Z,
   Peng Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo J,
   Ye C, Zhu S, Zhong N. 2020. Clinical Characteristics of Coronavirus Disease 2019 in
   China. N Engl J Med 382:1708–1720.
- Cui J, Li F, Shi Z-L. 2018. Origin and evolution of pathogenic coronaviruses. Nat Rev
   Microbiol 17:181–192.
- 788 5. Chen Y, Liu Q, Guo D. 2020. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 92:418–423.
- Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher
   S, De Jesus PD, Teriete P, Hull MV, Chang MW, Chan JF-W, Cao J, Poon VK-M, Herbert
   KM, Cheng K, Nguyen T-TH, Rubanov A, Pu Y, Nguyen C, Choi A, Rathnasinghe R,
   Schotsaert M, Miorin L, Dejosez M, Zwaka TP, Sit K-Y, Martinez-Sobrido L, Liu W-C,
   White KM, Chapman ME, Lendy EK, Glynne RJ, Albrecht R, Ruppin E, Mesecar AD,
   Johnson JR, Benner C, Sun R, Schultz PG, Su AI, García-Sastre A, Chatterjee AK, Yuen
- 796 K-Y, Chanda SK. 2020. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586:113–119.
- 798 7. Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, de Lamballerie X,
   799 Coutard B. 2020. In vitro screening of a FDA approved chemical library reveals potential
   800 inhibitors of SARS-CoV-2 replication. 1. Sci Rep 10:13093.
- Belouzard S, Machelart A, Sencio V, Vausselin T, Hoffmann E, Deboosere N, Rouillé Y, Desmarets L, Séron K, Danneels A, Robil C, Belloy L, Moreau C, Piveteau C, Biela A, Vandeputte A, Heumel S, Deruyter L, Dumont J, Leroux F, Engelmann I, Alidjinou EK, Hober D, Brodin P, Beghyn T, Trottein F, Déprez B, Dubuisson J. 2021. Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology. bioRxiv 2021.06.30.450483.
- Jeong GU, Song H, Yoon GY, Kim D, Kwon Y-C. 2020. Therapeutic Strategies Against
   COVID-19 and Structural Characterization of SARS-CoV-2: A Review. Front Microbiol
   11:1723.
- White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, Jangra S, Uccellini MB,
  Rathnasinghe R, Coughlan L, Martinez-Romero C, Batra J, Rojc A, Bouhaddou M, Fabius
  JM, Obernier K, Dejosez M, Guillén MJ, Losada A, Avilés P, Schotsaert M, Zwaka T,
  Vignuzzi M, Shokat KM, Krogan NJ, García-Sastre A. 2021. Plitidepsin has potent
- preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science 371:926–931.
- Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL,
   Luzuriaga K, Greenough TC, Choe H, Farzan M. 2003. Angiotensin-converting enzyme 2
   is a functional receptor for the SARS coronavirus. Nature 426:450–454.
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens
   TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 2020. SARS-

- CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181:271–280.
- Raj VS, Mou H, Smits SL, Dekkers DHW, Müller MA, Dijkman R, Muth D, Demmers
   JAA, Zaki A, Fouchier RAM, Thiel V, Drosten C, Rottier PJM, Osterhaus ADME, Bosch
   BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging
   human coronavirus-EMC. Nature 495:251–254.
- Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, Holmes
   KV. 1992. Human aminopeptidase N is a receptor for human coronavirus 229E. 6377.
   Nature 357:420–422.
- Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. 2010. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 84:12658–12664.
- Shirato K, Kawase M, Matsuyama S. 2013. Middle East Respiratory Syndrome
   Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2. J Virol
   87:12552–12561.
- Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4:1011–1033.
- Huang F, Li Y, Leung EL-H, Liu X, Liu K, Wang Q, Lan Y, Li X, Yu H, Cui L, Luo H,
   Luo L. 2020. A review of therapeutic agents and Chinese herbal medicines against SARS COV-2 (COVID-19). Pharmacol Res 158:104929.
- Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, Naiker M. 2020.
   Natural product-derived phytochemicals as potential agents against coronaviruses: A
   review. Virus Res 284:197989.
- Bertram S, Dijkman R, Habjan M, Heurich A, Gierer S, Glowacka I, Welsch K, Winkler M, Schneider H, Hofmann-Winkler H, Thiel V, Pöhlmann S. 2013. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol 87:6150–6160.
- Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N. 2019.
   TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol 93:e01815-18.
- 851 22. Belouzard S, Chu VC, Whittaker GR. 2009. Activation of the SARS coronavirus spike 852 protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A 853 106:5871–6.
- Kawase M, Shirato K, Matsuyama S, Taguchi F. 2009. Protease-Mediated Entry via the Endosome of Human Coronavirus 229E. J Virol 83:712–721.
- Vigant F, Lee J, Hollmann A, Tanner LB, Akyol Ataman Z, Yun T, Shui G, Aguilar HC,
  Zhang D, Meriwether D, Roman-Sosa G, Robinson LR, Juelich TL, Buczkowski H, Chou
  S, Castanho MARB, Wolf MC, Smith JK, Banyard A, Kielian M, Reddy S, Wenk MR,
  Selke M, Santos NC, Freiberg AN, Jung ME, Lee B. 2013. A mechanistic paradigm for
  broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog 9:e1003297.
- Costa L, Faustino MAF, Neves MGPMS, Cunha A, Almeida A. 2012. Photodynamic inactivation of mammalian viruses and bacteriophages. Viruses 4:1034–1074.
- Ratnoglik SL, Aoki C, Sudarmono P, Komoto M, Deng L, Shoji I, Fuchino H, Kawahara
   N, Hotta H. 2014. Antiviral activity of extracts from Morinda citrifolia leaves and
   chlorophyll catabolites, pheophorbide a and pyropheophorbide a, against hepatitis C virus.
   Microbiol Immunol 58:188–94.
- Bouslama L, Hayashi K, Lee J-B, Ghorbel A, Hayashi T. 2011. Potent virucidal effect of pheophorbide a and pyropheophorbide a on enveloped viruses. J Nat Med 65:229–233.
- 28. Zhang H-J, Tan GT, Hoang VD, Hung NV, Cuong NM, Soejarto DD, Pezzuto JM, Fong

- HHS. 2003. Natural Anti-HIV Agents. Part IV. Anti-HIV Constituents from Vatica cinerea.
   J Nat Prod 66:263–268.
- Yilmaz C, Gökmen V. 2016. Chlorophyll, p. 37–41. *In* Caballero, B, Finglas, PM, Toldrá,
   F (eds.), Encyclopedia of Food and Health. Academic Press, Oxford.
- Solymosi K, Mysliwa-Kurdziel B. 2017. Chlorophylls and their Derivatives Used in Food
   Industry and Medicine. Mini Rev Med Chem 17:1194–1222.
- 876 31. Humphrey AM. 1980. Chlorophyll. Food Chem 5:57–67.
- 32. Holden M. 1974. Chlorophyll degradation products in leaf protein preparations. J Sci Food
   Agric 25:1427–1432.
- Hajri A, Wack S, Meyer C, Smith MK, Leberquier C, Kedinger M, Aprahamian M. 2002.
   In Vitro and In Vivo Efficacy of Photofrin® and Pheophorbide a, a Bacteriochlorin, in Photodynamic Therapy of Colonic Cancer Cells¶. Photochem Photobiol 75:140–148.
- Roeder B, Naether D, Lewald T, Braune M, Nowak C, Freyer W. 1990. Photophysical
   properties and photodynamic activity in vivo of some tetrapyrroles. Biophys Chem 35:303–312.
- Hamblin MR. 2020. Photodynamic Therapy for Cancer: What's Past is Prologue. Photochem Photobiol 96:506–516.
- Wiehe A, O'Brien JM, Senge MO. 2019. Trends and targets in antiviral phototherapy. Photochem Photobiol Sci 18:2565–2612.
- Mariewskaya KA, Tyurin AP, Chistov AA, Korshun VA, Alferova VA, Ustinov AV. 2021.
   Photosensitizing Antivirals. Mol Basel Switz 26:3971.
- 891 38. Saide A, Lauritano C, Ianora A. 2020. Pheophorbide a: State of the Art. Mar Drugs 18:257.
- Synthesis? Front Plant Sci 11:1270.
   Clark NF, Taylor-Robinson AW. 2020. COVID-19 Therapy: Could a Chlorophyll
   Derivative Promote Cellular Accumulation of Zn2+ Ions to Inhibit SARS-CoV-2 RNA
- Hollmann A, Castanho MARB, Lee B, Santos NC. 2014. Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors. Biochem J 459:161–170.
- Vigant F, Santos NC, Lee B. 2015. Broad-spectrum antivirals against viral fusion. Nat Rev
   Microbiol 13:426–437.
- Tummino TA, Rezelj VV, Fischer B, Fischer A, O'Meara MJ, Monel B, Vallet T, White
   KM, Zhang Z, Alon A, Schadt H, O'Donnell HR, Lyu J, Rosales R, McGovern BL,
- Rathnasinghe R, Jangra S, Schotsaert M, Galarneau J-R, Krogan NJ, Urban L, Shokat KM, Kruse AC, García-Sastre A, Schwartz O, Moretti F, Vignuzzi M, Pognan F, Shoichet BK.
- 2021. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.
   Science 373:541–547.
- 906 43. Chen D, Lu S, Yang G, Pan X, Fan S, Xie X, Chen Q, Li F, Li Z, Wu S, He J. 2020. The
   907 seafood Musculus senhousei shows anti-influenza A virus activity by targeting virion
   908 envelope lipids. Biochem Pharmacol 177:113982.
- 44. Lamontagne J, Mills C, Mao R, Goddard C, Cai D, Guo H, Cuconati A, Block T, Lu X.
   2013. Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system. Antiviral Res 98:19–26.
- 913 45. Wang Y-T, Yang C-H, Huang K-S, Shaw J-F. 2021. Chlorophyllides: Preparation,
   914 Purification, and Application. Biomolecules 11:1115.
- 915 46. Guo H, Pan X, Mao R, Zhang X, Wang L, Lu X, Chang J, Guo J-T, Passic S, Krebs FC,
  916 Wigdahl B, Warren TK, Retterer CJ, Bavari S, Xu X, Cuconati A, Block TM. 2011.
- Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses,
- filoviruses, and arenaviruses. Antimicrob Agents Chemother 55:478–486.

- 47. Lebedeva NS, A Gubarev Y, O Koifman M, I Koifman O. 2020. The Application of
   Porphyrins and Their Analogues for Inactivation of Viruses. Mol Basel Switz 25:4368ol.
- 921 48. Cruz-Oliveira C, Almeida AF, Freire JM, Caruso MB, Morando MA, Ferreira VNS,
- Assunção-Miranda I, Gomes AMO, Castanho MARB, Da Poian AT. 2017. Mechanisms of
   Vesicular Stomatitis Virus Inactivation by Protoporphyrin IX, Zinc-Protoporphyrin IX, and
   Mesoporphyrin IX. Antimicrob Agents Chemother 61:e00053-17.
- 925 49. Gu C, Wu Y, Guo H, Zhu Y, Xu W, Wang Y, Zhou Y, Sun Z, Cai X, Li Y, Liu J, Huang Z,
   926 Yuan Z, Zhang R, Deng Q, Qu D, Xie Y. 2020. Protoporphyrin IX and verteporfin potently
   927 inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2. Sci
   928 Bull https://doi.org/10.1016/j.scib.2020.12.005.
- 50. Lu S, Pan X, Chen D, Xie X, Wu Y, Shang W, Jiang X, Sun Y, Fan S, He J. 2021. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses. Bioorganic Chem 107:104619.
- 51. Lim D-S, Ko S-H, Kim S-J, Park Y-J, Park J-H, Lee W-Y. 2002. Photoinactivation of vesicular stomatitis virus by a photodynamic agent, chlorophyll derivatives from silkworm excreta. J Photochem Photobiol B 67:149–156.
- 935 52. Almeida A, Faustino MAF, Neves MGPMS. 2020. Antimicrobial Photodynamic Therapy936 in the Control of COVID-19. Antibiotics 9:320.
- 53. Sabino CP, Ball AR, Baptista MS, Dai T, Hamblin MR, Ribeiro MS, Santos AL, Sellera
   FP, Tegos GP, Wainwright M. 2020. Light-based technologies for management of COVID 19 pandemic crisis. J Photochem Photobiol B 212:111999.
- Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J. 2011. Photodynamic therapy of cancer: an update. CA Cancer J Clin 61:250–281.
- de Vries RD, Schmitz KS, Bovier FT, Predella C, Khao J, Noack D, Haagmans BL, Herfst S, Stearns KN, Drew-Bear J, Biswas S, Rockx B, McGill G, Dorrello NV, Gellman SH, Alabi CA, de Swart RL, Moscona A, Porotto M. 2021. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science 371:1379–1382.
- Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. 1994. Formation
   and intracellular localization of hepatitis C virus envelope glycoprotein complexes
   expressed by recombinant vaccinia and Sindbis viruses. J Virol 68:6147–6160.
- yan den Worm SHE van den, Eriksson KK, Zevenhoven JC, Weber F, Züst R, Kuri T,
   Dijkman R, Chang G, Siddell SG, Snijder EJ, Thiel V, Davidson AD. 2012. Reverse
   Genetics of SARS-Related Coronavirus Using Vaccinia Virus-Based Recombination.
   PLOS ONE 7:e32857.
- 58. Goueslain L, Alsaleh K, Horellou P, Roingeard P, Descamps V, Duverlie G, Ciczora Y,
   Wychowski C, Dubuisson J, Rouillé Y. 2010. Identification of GBF1 as a Cellular Factor
   Required for Hepatitis C Virus RNA Replication. J Virol 84:773–787.
- Duvet S, Chirat F, Mir A-M, Verbert A, Dubuisson J, Cacan R. 2000. Reciprocal relationship between α1,2 mannosidase processing and reglucosylation in the rough endoplasmic reticulum of Man-P-Dol deficient cells. Eur J Biochem 267:1146–1152.
- 961 60. Rouillé Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, Belouzard S,
   962 McKeating J, Patel AH, Maertens G, Wakita T, Wychowski C, Dubuisson J. 2006.
   963 Subcellular Localization of Hepatitis C Virus Structural Proteins in a Cell Culture System
   964 That Efficiently Replicates the Virus. J Virol 80:2832–2841.
- Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset
   F-L, Dubuisson J. 2004. Characterization of functional hepatitis C virus envelope
   glycoproteins. J Virol 78:2994–3002.

## FIGURE LEGENDS

Figure 1. Identification of Pba as active compound in *Mallotus oppositifolius* using bioguided fractionation of plant extracts. (A) Huh-7 cells were inoculated with HCoV-229E in the presence of various plant extracts at 25  $\mu$ g/mL. Cells were lysed 7 h post-inoculation and luciferase activity quantified. (B) Huh-7 cells were inoculated with HCoV-229E in the presence of sub-extracts of Mo (methylene chloride, MC; ethanol/water (50:50), EtOH/w; water, H<sub>2</sub>0; left), fractions of Mo MC sub-extract (middle), or sub-fractions of F7 fraction (right panel) at 25  $\mu$ g/mL. Cells were lysed 7 h post-inoculation and luciferase activity quantified. (C) Huh-7 cells were inoculated with HCoV-229E-Luc in the presence of Pba extracted from Mo (Pba F7.7) or commercial Pba (Pba com) at different concentrations. At 1 h p.i., cells were washed and fresh compounds were added to the cells for 6 h after which cells were lysed to quantify luciferase activity. Data are expressed relative to the control DMSO. Results are expressed as mean  $\pm$  SEM of 3 experiments.

**Figure 2. Pba inhibits various HCoVs.** For infection assays, cells were inoculated with HCoV-229E (Huh-7 cells), SARS-CoV-2 (Vero-E6 cells) and MERS-CoV (Huh-7 cells) in presence of various concentrations of Pba. At 1 h p.i, cells were washed and fresh compounds were added to the cells for 9 h (HCoV-229E) or 16 h (SARS-CoV-2 and MERS-CoV) and the supernatants were collected for infectivity titration. For toxicity assays, cells were incubated with Pba at different concentrations for 24 h. MTS assay was performed to monitor cell viability. For both infection and toxicity tests, cells were exposed to the light of the cabinet for 10 min, once upon inoculation, once after a 1 h incubation. Results are expressed as mean  $\pm$  SEM of 3 experiments.

Figure 3. Pba inhibits viral entry by a direct action on the viral particle. (A) Huh-7 and Huh-7-TMPRSS2 cells were inoculated with HCoV-229E-Luc in the presence of various concentrations Pba. At 1 h p.i, cells were washed and fresh compounds were added to the cells for 6 h after which the cells were lysed to quantify luciferase activity. Data are expressed relative to the control DMSO. (B) Pba at 2 µM was added at different time points during infection of Huh-7-TMPRSS2 cells by HCoV-229E-Luc, either 1 h before inoculation (pre-treatment), or 1 h during inoculation (Inoculation), or for 6 h post-inoculation (p.i.-end), after 1 h post-inoculation till the end (1 h p.i.-end), or 2 h post-inoculation till the end (2 h p.i.end). Cells were lysed 7 h after the inoculation and luciferase activity quantified. (C) A similar experiment was performed in Vero-81 cells inoculated with SARS-CoV-2 in the presence of Pba at 1 µM or chloroquine at 10 µM at different time points. Cells were lysed 16 h post-inoculation and the viral nucleocapsid protein was detected by Western blot. The graph represents the quantification of the band intensity corresponding to the N protein, relative to the DMSO control for each time point. (D) Huh-7 cells were inoculated with HCoV-229E-Luc in the presence of 0.2 or 2 µM Pba, or with HCoV-229E-Luc previously treated with 2 µM Pba and then diluted 10 times, leading to a concentration of 0.2 µM Pba for the inoculation period (2  $\mu$ M > 0.2  $\mu$ M). The amount of virus used for inoculation was kept constant in the different conditions and all the samples were exposed to the light for 10 min. At 7 h post-inoculation, cells were lysed and luciferase activity was quantified. \*, P<0.05; \*\*\*, P<0.005.

**Figure 4. Pba inhibits viral entry at the fusion step.** (**A**) Huh-7-TMPRSS2 cells were inoculated with HCoV-229E for 1 h at 4°C in the presence of DMSO, or 4.1 and 8.2 μM Pba. Cells were washed thrice with ice-cold PBS, and total RNA was extracted. Bound HCoV-229E virions were detected by quantification of HCoV-229E gRNA by qRT-PCR. Relative binding is expressed as the percentage of the control (DMSO) for which the 100% value was arbitrarily attributed. Mean values ± SEM (error bars) of three independent experiments are presented. n.s., not significant. (**B**) HCoV-229E was incubated with Pba at different concentration and was bound to Huh-7 cells for 1 h in the absence (control) or presence (trypsin) of NH<sub>4</sub>Cl at 4°C. In the later condition, fusion was induced by 3 μg/mL trypsin for 5 min at 37 °C in the presence of NH<sub>4</sub>Cl. Cells were lysed 7 h post-infection and luciferase activity quantified. Infectivity is expressed as the percentage of the control (DMSO) for which the 100% value was arbitrarily attributed. Mean values ± SEM (error bars) of three independent experiments are presented. (**C**) Vero-81 cells transiently expressing SARS-CoV-2 spike protein were incubated with or without Pba at 1 μM from 6 to 24 h p.i., after which syncytia were visualized by immunofluorescence. Images were acquired on an Evos M5000 imaging system (Thermo Fisher Scientific).

Figure 5. The antiviral activity of Pba depends on light exposure and its ability to generate singlet oxygen species. HCoV-229E-Luc (A) and SARS-CoV-2 (B) were incubated with Pba at given concentration under the light of the laminar flow cabinet. At different time points of light exposure, the mixture was used to inoculate Huh-7 cells or Vero-81 cells, respectively. At 7 h (HCoV-229E-Luc) or 16 h (SARS-CoV-2) post-inoculation, cells were lysed and infection quantified as described previously. (C) Pba at 0.5 or 1  $\mu$ M was mixed with 10 mM Trolox or 10 mM NaN<sub>3</sub> in DMEM and HCoV-229E-Luc was added to the mixture prior to inoculation of Huh-7 cells for 1 h at 37°C. Inoculum and compounds were removed and replaced with culture medium for 6 h. Cells were lysed and luciferase activity quantified. Infectivity is expressed as the percentage of infection relative to the control (DMSO) to which the 100% value was arbitrarily attributed. Mean values  $\pm$  SEM (error bars) of three independent experiments are presented.

Figure 6. Pba renders virions resistant to osmotic shock. HCoV-229E were incubated in the presence or absence of Pba at  $10~\mu\text{M}$  with or without 30 min light exposure, after which the particles were subjected to normal medium conditions (100~mM NaCl) or to an osmotic shock of 400~mM NaCl for 30~sec. Virions were fixed with PFA and samples were treated for CryoEM observation. Images are representative of 30~independent images of 2~independent experiments. Scale bar: 50~nm.

Figure 7. Pba is a broad-spectrum antiviral agent against enveloped viruses. (A) MERSpp, HCoV-229Epp, VSVpp, and SARS-2pp were preincubated with Pba at the indicated concentration either under light for 30 min (Light) or without light (Dark) prior to inoculation of Huh-7 cells expressing ACE2 and TMPRSS2 for 2 h. At 46 h post-inoculation, cells were lysed and luciferase activity was quantified. Infectivity is expressed as the percentage relative to the control (DMSO) to which the 100% value was arbitrarily attributed. Mean values ± SEM (error bars) of three different experiments are presented. (B). Different viruses were incubated with Pba at 1 and 2.5 μM under light condition for 30 min prior to inoculation. Cells were fixed at different time points depending on the virus (see Materials and Methods section for details) and subjected to immunofluorescence labelling. Infectivity is expressed as the

percentage relative to the control (DMSO). Mean values  $\pm$  SEM (error bars) of three different experiments are presented.

**Figure 8.** Antiviral efficacy of Pba in human primary bronchial epithelial cells. Mucilair<sup>TM</sup> cells were inoculated with SARS-CoV-2 or MERS-CoV in the presence of Pba at 0.25 or 2.5 μM for 1 h at the apical side. The cells were left for 10 min under the light of the cabinet before being put in the incubator. Inoculum was removed 1 h post-inoculation. Remdesivir (Rem) at 5 μM was added in the basolateral medium. The cells were additionally exposed to the light for 10 min at 24 h, 48 h and 72 h post-inoculation. 72 h post-inoculation, viruses were collected from the apical surface, and cells were lysed to extract RNA. Viral RNA was quantified by qRT-PCR and viral titers were determined by infectivity titrations for SARS-CoV-2 (**A**) and MERS-CoV (**B**). For RNA quantification, data are expressed relative to the control DMSO. Results are expressed as mean  $\pm$  SEM of 3 experiments. Viral titers are representative of three independent experiments. Toxicity of Pba was measures in Mucilair<sup>TM</sup> treated with Pba at 0.25 and 2.5 μM by measuring either LDH secretion (**C**) or trans-epithelial electrical resistance (**D**) at 24 h, 48 h and 72 h incubation. As a control, cells were lysed with lysis solution as described in materials and methods section. Results are expressed as mean  $\pm$  SEM of 2 experiments. \*, P<0.05; \*\*\*, P<0.005; n.s., not significant.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8